Version 1
: Received: 30 April 2023 / Approved: 1 May 2023 / Online: 1 May 2023 (04:18:06 CEST)
How to cite:
Akbar, S.M.F.; Al Mahtab, M.; Hiasa, Y. Evolving Therapies Targeting the Viruses and Host in Hbv/Hdv-Coinfection; Analyses of the Present Strategies. Preprints2023, 2023050014. https://doi.org/10.20944/preprints202305.0014.v1
Akbar, S.M.F.; Al Mahtab, M.; Hiasa, Y. Evolving Therapies Targeting the Viruses and Host in Hbv/Hdv-Coinfection; Analyses of the Present Strategies. Preprints 2023, 2023050014. https://doi.org/10.20944/preprints202305.0014.v1
Akbar, S.M.F.; Al Mahtab, M.; Hiasa, Y. Evolving Therapies Targeting the Viruses and Host in Hbv/Hdv-Coinfection; Analyses of the Present Strategies. Preprints2023, 2023050014. https://doi.org/10.20944/preprints202305.0014.v1
APA Style
Akbar, S.M.F., Al Mahtab, M., & Hiasa, Y. (2023). Evolving Therapies Targeting the Viruses and Host in Hbv/Hdv-Coinfection; Analyses of the Present Strategies. Preprints. https://doi.org/10.20944/preprints202305.0014.v1
Chicago/Turabian Style
Akbar, S.M.F., Mamun Al Mahtab and Yoichi Hiasa. 2023 "Evolving Therapies Targeting the Viruses and Host in Hbv/Hdv-Coinfection; Analyses of the Present Strategies" Preprints. https://doi.org/10.20944/preprints202305.0014.v1
Abstract
Coinfection of B virus (HBV) and hepatitis Delta virus (HDV) lead to severe forms of progressive liver diseases. However, commercially available antiviral drugs have shown considerable adverse effects and low efficacy in managing these patients. Thus, there is a pressing need to develop new, innovative, and evidence-based therapies for these pathological entities. In line with this, some investigators have attempted to develop anti-viral drugs targeting HBV/HDV coinfection. In another development, investigators have also attempted to establish immune therapy targeting for HBV infection as recovery or effective control of HBV infection also lead to efficient control of HDV infection. This review has discussed an account of the evolving antiviral and immune therapeutic drugs for HBV/HDV infection. Also, based on current scientific knowledge how we have described the pros and cons of these drugs as no suitable drug has been developed during the last forty years for treating HBV infection except the availability of two” repurposed drugs”; interferons and its derivatives and nucleoside analogs, for managing HBV or HBV/HDV coinfection. It seems that an evolving and innovative therapeutic regimen that combines both antiviral drugs and immune modulators may be the best and realistic option for management of HBV/HDV coinfection.
Keywords
HBV/HDV coinfection; Evolving antiviral drugs; innovative immune therapeutic agents; combination of antiviral and immune therapy
Subject
Public Health and Healthcare, Physical Therapy, Sports Therapy and Rehabilitation
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
